Author/Authors :
Hoseinkhani, Zohreh Medical Biology Research Center - Kermanshah University of Medical Sciences, Kermanshah, Iran , Khodarahmi, Reza Medical Biology Research Center - Kermanshah University of Medical Sciences, Kermanshah, Iran , Sadeghalvad, Mona Medical Biology Research Center - Kermanshah University of Medical Sciences, Kermanshah, Iran , Norooznezhad, Fathemeh Medical Biology Research Center - Kermanshah University of Medical Sciences, Kermanshah, Iran , Mansouri, Kamran Medical Biology Research Center - Kermanshah University of Medical Sciences, Kermanshah, Iran
Abstract :
CYP2C9 and VKORC1-1639 G>A genes as the genetic factors significantly
influence the warfarin dose requirement in individuals. The patients
with genetic variations in CYP2C9 and VKORC1 are at increased risk of
adverse warfarin-related events. A young patient with atrial septal
defect being highly sensitive to normal daily dose of warfarin was
subjected to the study. The patient consented to genetic testing.
Furthermore, DNA was isolated and PCR-RFLP performed. The patient
required low warfarin dose of 11 mg/week to achieve the target
international normalized ratio (INR). Genetic testing revealed that the
patient carried VKORC1-1639 AA and CYP2C9*1*2 genotypes. Our
findings reaffirm the significance of pharmacogenetic analysis prior to
the warfarin therapy to achieve an efficient treatment and the least
side/adverse drug effects.
Keywords :
CYP2C9 genotype , VKORC1 genotype , International normalized ratio , Warfarin
